ADMS Adamas Pharmaceuticals, Inc.

16.12
-0.05  -0.31%
Previous Close 16.17
Open 16.17
Price To book 2.47
Market Cap 354.35M
Shares 21,982,000
Volume 79,947
Short Ratio 27.37
Av. Daily Volume 156,174

SEC filingsSee all SEC filings

  1. EFFECT - Notice of Effectiveness 162011664
  2. CORRESP [Cover] - Correspondence
  3. UPLOAD [Cover] - SEC-generated letter
  4. S-3 - Registration statement under Securities Act of 1933 161971636
  5. 8-K - Current report 161971588

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved Dec 24 2014
Namzaric
Moderate to severe dementia of the Alzheimer’s type.
Phase 2 data released early June 2016. Evaluating Phase 3 pathway.
ADS-5102
Multiple sclerosis (MS)
PDUFA date August 24, 2017.
ADS-5102
Levodopa-Induced Dyskinesia

Latest News

  1. Adamas Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ADMS) : January 20, 2017
  2. Adamas Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ADMS-US : January 19, 2017
  3. Adamas Pharmaceuticals Inc (ADMS) Is Up On PDUFA: What’s Next?
  4. Adamas Pharmaceuticals (ADMS) in Focus: Stock Up 5.4%
  5. Adamas Outlines Key 2017 Priorities and Highlights 2016 Achievements
  6. Adamas Announces U.S. FDA Acceptance of ADS-5102 New Drug Application for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinson's Disease
  7. Adamas Announces U.S. FDA Acceptance of ADS-5102 New Drug Application for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinson's Disease
  8. Adamas Pharmaceuticals Completes Phase 1 Clinical Trial of ADS-4101 for Treatment of Partial Onset Seizures in Patients with Epilepsy
  9. Adamas Pharmaceuticals Completes Phase 1 Clinical Trial of ADS-4101 for Treatment of Partial Onset Seizures in Patients with Epilepsy
  10. Mylan (MYL) Announces Multiple Generic Launches in the U.S.
  11. Mylan/Biocon's Herceptin Biosimilar Phase III Data Published
  12. Mylan (MYL) Launches Authorized Generic EpiPen at $300
  13. Is Craft Brew Alliance Inc (BREW) A Good Stock To Buy?
  14. Is Adamas Pharmaceuticals Inc (ADMS) A Good Stock To Buy?
  15. Adamas Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ADMS-US : December 5, 2016
  16. Adamas Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ADMS-US : November 23, 2016
  17. Adamas Pharmaceuticals to Present at the 28th Annual Piper Jaffray Healthcare Conference
  18. Moving Average Crossover Alert: Adamas Pharma (ADMS)
  19. ADAMAS PHARMACEUTICALS INC Financials
  20. ETF’s with exposure to Adamas Pharmaceuticals, Inc. : November 10, 2016

SEC Filings

  1. EFFECT - Notice of Effectiveness 162011664
  2. CORRESP [Cover] - Correspondence
  3. UPLOAD [Cover] - SEC-generated letter
  4. S-3 - Registration statement under Securities Act of 1933 161971636
  5. 8-K - Current report 161971588
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 161971516
  7. 8-K - Current report 161897741
  8. SC 13G - Statement of acquisition of beneficial ownership by individuals 161881110
  9. 8-K - Current report 161807581
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 161807304